Lab
Clinical Pathology Laboratories, INC.
Clinical Pathology Laboratories, INC. was paid $159.40M by Medicaid between Jan 2018 and Dec 2024, across 496 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 11% of everything it billed.
33Billing provider infoCLINICAL PATHOLOGY LABORATORIES, INC.
AUSTIN, TX 78754
AUSTIN, TX 78754
33aNPI1194769497assigned 06/16/2006
33bProvider typeClinical Medical Laboratory
28Total paid$159.40M
24GClaims17,848,189
24DCodes billed496
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#4 of 436
Median peer was paid$17K
This provider vs. median9,241×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,764,699 | $11.48M | |
| 2019 | 1,766,786 | $10.62M | |
| 2020 | 1,924,481 | $18.80M | |
| 2021 | 3,370,043 | $33.70M | |
| 2022 | 3,244,811 | $35.43M | |
| 2023 | 3,253,477 | $28.55M | |
| 2024incomplete | 2,523,892 | $20.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 373,787 | 256,955 | $18.02M |
| 80050 | General health panel | 6.4% | 439,483 | 413,152 | $10.16M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.7% | 453,233 | 417,506 | $9.13M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.6% | 446,051 | 411,019 | $9.00M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 4.5% | 235,667 | 176,317 | $7.21M |
| 80061 | Lipid panel | 3.6% | 1,101,129 | 1,033,779 | $5.81M |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.2% | 434,608 | 400,489 | $5.05M |
| 80081 | 2.7% | 102,458 | 97,580 | $4.37M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.7% | 335,801 | 311,458 | $4.33M |
| 80053 | Comprehensive metabolic panel | 2.4% | 1,096,177 | 1,015,623 | $3.87M |
| 84443 | Thyroid stimulating hormone (TSH) | 2.2% | 704,167 | 655,934 | $3.53M |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.2% | 914,226 | 848,801 | $3.46M |
484 more codes
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 2.1% | 249,114 | $3.42M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.1% | 213,806 | $3.31M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 1,144,227 | $3.12M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.9% | 81,935 | $3.10M |
| 81514 | 1.8% | 36,463 | $2.85M | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.8% | 150,438 | $2.81M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.2% | 97,972 | $1.96M |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.2% | 478,296 | $1.84M |
| 86003 | 1.1% | 75,203 | $1.72M | |
| 80074 | <1% | 83,272 | $1.45M | |
| 84439 | <1% | 349,576 | $1.38M | |
| 86803 | <1% | 183,699 | $1.29M | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 23,480 | $1.15M |
| 82607 | <1% | 167,117 | $1.13M | |
| 87800 | <1% | 37,763 | $991K | |
| 86235 | <1% | 22,990 | $957K | |
| 84403 | <1% | 69,960 | $934K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 14,557 | $881K |
| 84702 | <1% | 107,228 | $853K | |
| 86696 | <1% | 74,357 | $825K | |
| 84481 | <1% | 111,298 | $804K | |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | <1% | 2,617 | $769K |
| 87536 | <1% | 18,905 | $766K | |
| 86592 | <1% | 315,859 | $734K | |
| 83013 | <1% | 24,474 | $734K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 10,529 | $710K |
| 86480 | <1% | 24,450 | $683K | |
| 82105 | <1% | 76,733 | $673K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 8,749 | $643K |
| 82746 | <1% | 94,319 | $642K | |
| 87070 | <1% | 127,439 | $604K | |
| 83525 | <1% | 88,480 | $549K | |
| 87340 | <1% | 111,154 | $546K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 788,712 | $546K |
| 82670 | <1% | 34,963 | $531K | |
| 84153 | <1% | 73,103 | $520K | |
| 87522 | Neg quan hep c or qual rna | <1% | 24,130 | $512K |
| 87186 | <1% | 134,743 | $509K | |
| 86695 | <1% | 67,660 | $507K | |
| 88141 | <1% | 35,572 | $497K | |
| 83970 | <1% | 39,593 | $479K | |
| 87081 | <1% | 129,880 | $477K | |
| 87481 | <1% | 40,654 | $454K | |
| 86376 | <1% | 57,673 | $427K | |
| 86038 | <1% | 72,877 | $425K | |
| 83001 | <1% | 43,463 | $422K | |
| 84146 | <1% | 43,386 | $420K | |
| 87077 | <1% | 119,180 | $416K | |
| 82728 | <1% | 75,014 | $404K | |
| 83550 | <1% | 110,364 | $399K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 11,452 | $397K |
| 84270 | <1% | 34,815 | $395K | |
| 83655 | <1% | 60,247 | $380K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 13,133 | $373K |
| 87902 | <1% | 3,277 | $369K | |
| 83540 | <1% | 138,782 | $356K | |
| 86706 | <1% | 64,322 | $353K | |
| 87529 | <1% | 29,129 | $346K | |
| 83880 | <1% | 28,650 | $343K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 4,914 | $341K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 3,233 | $336K |
| 86780 | <1% | 44,914 | $329K | |
| 83002 | <1% | 34,430 | $328K | |
| 82677 | <1% | 24,220 | $326K | |
| 86704 | <1% | 51,039 | $319K | |
| 84144 | <1% | 27,871 | $317K | |
| 86708 | <1% | 50,542 | $303K | |
| 86762 | <1% | 37,160 | $295K | |
| 84436 | <1% | 101,435 | $293K | |
| 86769 | <1% | 11,971 | $289K | |
| 82043 | <1% | 139,624 | $273K | |
| 82570 | <1% | 145,828 | $259K | |
| 86850 | <1% | 54,158 | $254K | |
| 81003 | <1% | 269,664 | $246K | |
| 82950 | <1% | 100,180 | $242K | |
| 85027 | <1% | 84,058 | $240K | |
| 86787 | <1% | 35,160 | $234K | |
| 86336 | <1% | 24,343 | $216K | |
| 82652 | <1% | 19,844 | $214K | |
| 86160 | <1% | 24,288 | $212K | |
| 82785 | <1% | 23,302 | $211K | |
| 83516 | <1% | 44,746 | $207K | |
| 82627 | <1% | 17,628 | $203K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 69,582 | $201K |
| 87631 | <1% | 3,089 | $200K | |
| 83735 | <1% | 72,159 | $195K | |
| 88142 | <1% | 17,776 | $194K | |
| 86140 | <1% | 81,192 | $191K | |
| 84480 | <1% | 34,192 | $190K | |
| 83020 | <1% | 28,728 | $189K | |
| 82951 | <1% | 28,164 | $186K | |
| 84479 | <1% | 67,211 | $182K | |
| 87147 | <1% | 66,053 | $174K | |
| 81001 | <1% | 130,560 | $170K | |
| 86665 | <1% | 8,613 | $167K | |
| 80164 | <1% | 32,792 | $166K | |
| 84681 | <1% | 15,465 | $165K | |
| 84550 | <1% | 100,261 | $156K | |
| 86431 | <1% | 56,506 | $156K | |
| 86800 | <1% | 18,829 | $155K | |
| 87901 | <1% | 1,091 | $152K | |
| 80323 | <1% | 13,989 | $151K | |
| 86694 | <1% | 20,310 | $150K | |
| 86361 | <1% | 12,142 | $146K | |
| 86147 | <1% | 4,979 | $140K | |
| 80349 | <1% | 25,158 | $140K | |
| 86225 | <1% | 21,405 | $137K | |
| 85652 | <1% | 111,157 | $133K | |
| 83498 | <1% | 8,676 | $129K | |
| 87209 | <1% | 15,447 | $122K | |
| 80076 | <1% | 30,700 | $120K | |
| 87507 | <1% | 1,996 | $117K | |
| 87660 | <1% | 14,244 | $116K | |
| 83690 | <1% | 34,513 | $115K | |
| 87799 | <1% | 4,835 | $113K | |
| 82248 | <1% | 60,900 | $109K | |
| 82533 | <1% | 13,418 | $108K | |
| 87480 | <1% | 14,184 | $108K | |
| 82784 | <1% | 19,322 | $108K | |
| 87511 | <1% | 8,331 | $107K | |
| 86200 | <1% | 17,409 | $105K | |
| 87653 | <1% | 6,067 | $102K | |
| 82024 | <1% | 4,760 | $101K | |
| 84445 | <1% | 3,795 | $97K | |
| 86364 | <1% | 18,257 | $97K | |
| 86039 | <1% | 18,667 | $95K | |
| 82550 | <1% | 38,256 | $94K | |
| 85610 | <1% | 63,722 | $92K | |
| 87510 | <1% | 14,210 | $90K | |
| 82150 | <1% | 27,549 | $87K | |
| 87046 | <1% | 17,125 | $87K | |
| 87045 | <1% | 16,975 | $86K | |
| 86360 | <1% | 4,727 | $86K | |
| 85730 | <1% | 35,851 | $82K | |
| 80069 | <1% | 31,355 | $82K | |
| 86141 | <1% | 12,535 | $82K | |
| 82977 | <1% | 26,527 | $80K | |
| 80361 | <1% | 11,186 | $80K | |
| 87512 | <1% | 3,574 | $80K | |
| 86901 | <1% | 45,164 | $77K | |
| 86900 | <1% | 46,478 | $76K | |
| 84156 | <1% | 55,271 | $76K | |
| 80358 | <1% | 10,371 | $75K | |
| 85660 | <1% | 26,773 | $74K | |
| 86258 | <1% | 14,203 | $74K | |
| 86008 | <1% | 4,924 | $72K | |
| 80365 | <1% | 10,077 | $71K | |
| 86317 | <1% | 2,593 | $70K | |
| 80376 | <1% | 6,696 | $69K | |
| 80348 | <1% | 10,172 | $68K | |
| 80373 | <1% | 6,415 | $67K | |
| 84100 | <1% | 41,299 | $67K | |
| 88342 | <1% | 1,651 | $66K | |
| 80364 | <1% | 8,057 | $65K | |
| 80347 | <1% | 8,051 | $65K | |
| 87177 | <1% | 15,093 | $64K | |
| 80372 | <1% | 5,943 | $63K | |
| 82672 | <1% | 5,479 | $63K | |
| 82947 | <1% | 34,268 | $62K | |
| 80354 | <1% | 7,858 | $61K | |
| 80326 | <1% | 8,985 | $61K | |
| 80337 | <1% | 6,820 | $60K | |
| 80357 | <1% | 6,235 | $60K | |
| 80055 | <1% | 2,084 | $55K | |
| 80177 | <1% | 12,602 | $53K | |
| 81025 | <1% | 12,301 | $52K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 9,204 | $52K |
| 82274 | <1% | 8,858 | $52K | |
| 87906 | <1% | 701 | $51K | |
| 80355 | <1% | 7,010 | $50K | |
| 85060 | <1% | 5,193 | $48K | |
| 86664 | <1% | 5,388 | $48K | |
| 82140 | <1% | 9,996 | $48K | |
| 83615 | <1% | 18,321 | $48K | |
| 84703 | <1% | 11,455 | $48K | |
| 83090 | <1% | 6,973 | $47K | |
| 80330 | <1% | 5,253 | $47K | |
| 86146 | <1% | 2,112 | $47K | |
| 82952 | <1% | 23,170 | $47K | |
| 84425 | <1% | 5,908 | $46K | |
| 84484 | <1% | 7,729 | $45K | |
| 87338 | <1% | 7,675 | $44K | |
| 85007 | <1% | 28,916 | $44K | |
| 82247 | <1% | 19,240 | $44K | |
| 84305 | <1% | 3,833 | $44K | |
| 84154 | <1% | 7,425 | $43K | |
| 86663 | <1% | 5,555 | $43K | |
| 82747 | <1% | 6,269 | $41K | |
| 84134 | <1% | 8,467 | $40K | |
| 83014 | <1% | 11,285 | $39K | |
| 85246 | <1% | 3,265 | $39K | |
| 80178 | <1% | 13,636 | $39K | |
| 86709 | <1% | 6,754 | $38K | |
| 85245 | <1% | 3,164 | $38K | |
| 84207 | <1% | 3,652 | $37K | |
| 82397 | <1% | 5,836 | $36K | |
| 80344 | <1% | 4,111 | $36K | |
| 83520 | <1% | 4,683 | $35K | |
| 84466 | <1% | 6,300 | $35K | |
| 83789 | <1% | 2,733 | $35K | |
| 80352 | <1% | 3,789 | $34K | |
| 82239 | <1% | 3,969 | $32K | |
| 85379 | <1% | 7,379 | $32K | |
| 86304 | <1% | 4,090 | $32K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,817 | $31K |
| 82553 | <1% | 4,699 | $30K | |
| 83993 | <1% | 3,288 | $30K | |
| 80371 | <1% | 3,812 | $30K | |
| 85240 | <1% | 3,198 | $30K | |
| 85045 | <1% | 16,623 | $30K | |
| 86870 | <1% | 2,999 | $29K | |
| 86341 | <1% | 2,388 | $29K | |
| 88304 | <1% | 1,141 | $29K | |
| 87075 | <1% | 6,372 | $29K | |
| 86645 | <1% | 3,009 | $28K | |
| 80185 | <1% | 7,061 | $28K | |
| 85018 | <1% | 23,197 | $28K | |
| 82378 | <1% | 5,530 | $28K | |
| 84460 | <1% | 13,041 | $28K | |
| 80197 | <1% | 7,900 | $28K | |
| 84165 | <1% | 9,811 | $28K | |
| 80156 | <1% | 6,327 | $27K | |
| 86735 | <1% | 3,396 | $26K | |
| 87255 | <1% | 1,337 | $26K | |
| 86644 | <1% | 3,298 | $25K | |
| 88307 | <1% | 200 | $25K | |
| 86335 | <1% | 4,268 | $24K | |
| 80183 | <1% | 5,602 | $24K | |
| 82542 | <1% | 2,065 | $24K | |
| 80345 | <1% | 4,353 | $24K | |
| 83698 | <1% | 1,652 | $23K | |
| 87581 | <1% | 1,333 | $23K | |
| 86765 | <1% | 3,190 | $22K | |
| 87486 | <1% | 1,321 | $21K | |
| 84432 | <1% | 2,243 | $21K | |
| 87449 | <1% | 4,291 | $21K | |
| 82088 | <1% | 1,199 | $21K | |
| 88312 | <1% | 412 | $21K | |
| 86255 | <1% | 4,929 | $20K | |
| 85613 | <1% | 4,141 | $20K | |
| 82575 | <1% | 3,745 | $20K | |
| 88341 | <1% | 327 | $19K | |
| 86705 | <1% | 3,474 | $19K | |
| 87497 | <1% | 1,177 | $18K | |
| 84478 | <1% | 6,254 | $18K | |
| 87493 | <1% | 1,263 | $18K | |
| 87563 | <1% | 1,054 | $18K | |
| 87517 | <1% | 1,722 | $18K | |
| 86757 | <1% | 1,586 | $18K | |
| 86777 | <1% | 2,340 | $17K | |
| 84450 | <1% | 8,974 | $17K | |
| 86738 | <1% | 2,846 | $17K | |
| 86060 | <1% | 4,505 | $17K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 265 | $16K |
| 80159 | <1% | 2,963 | $16K | |
| 84630 | <1% | 2,891 | $16K | |
| 80324 | <1% | 3,187 | $16K | |
| 82166 | <1% | 1,254 | $16K | |
| 80346 | <1% | 2,691 | $16K | |
| 82565 | <1% | 9,985 | $15K | |
| 85014 | <1% | 13,943 | $15K | |
| 85384 | <1% | 2,901 | $15K | |
| 80175 | <1% | 3,749 | $15K | |
| 87040 | <1% | 3,807 | $15K | |
| 82390 | <1% | 3,131 | $15K | |
| 82103 | <1% | 2,484 | $15K | |
| 86593 | <1% | 6,404 | $15K | |
| 81511 | <1% | 4,612 | $15K | |
| 86381 | <1% | 1,709 | $14K | |
| 86812 | <1% | 1,338 | $14K | |
| 83010 | <1% | 2,961 | $14K | |
| 87088 | <1% | 3,055 | $14K | |
| 80370 | <1% | 1,571 | $14K | |
| 86702 | <1% | 3,726 | $14K | |
| 83883 | <1% | 3,642 | $14K | |
| 86308 | <1% | 4,491 | $14K | |
| 83695 | <1% | 2,486 | $13K | |
| 80359 | <1% | 2,914 | $13K | |
| 81596 | <1% | 1,022 | $12K | |
| 81000 | <1% | 8,207 | $12K | |
| 82671 | <1% | 757 | $11K | |
| 84446 | <1% | 2,018 | $11K | |
| 80368 | <1% | 1,211 | $11K | |
| 82465 | <1% | 5,027 | $11K | |
| 87329 | <1% | 1,817 | $11K | |
| 81015 | <1% | 8,165 | $11K | |
| 86778 | <1% | 1,465 | $11K | |
| 86677 | <1% | 2,049 | $11K | |
| 84590 | <1% | 2,180 | $11K | |
| 80341 | <1% | 1,418 | $11K | |
| 82787 | <1% | 1,709 | $10K | |
| 86015 | <1% | 2,187 | $10K | |
| 85385 | <1% | 1,810 | $10K | |
| 87350 | <1% | 1,563 | $10K | |
| 82330 | <1% | 2,190 | $10K | |
| 86036 | <1% | 2,209 | $10K | |
| 87280 | <1% | 1,493 | $10K | |
| 87625 | <1% | 524 | $10K | |
| 82731 | <1% | 346 | $10K | |
| 84163 | <1% | 1,312 | $9K | |
| 82172 | <1% | 5,112 | $9K | |
| 82610 | <1% | 1,194 | $9K | |
| 87184 | <1% | 2,656 | $9K | |
| 86611 | <1% | 1,484 | $9K | |
| 80320 | <1% | 1,357 | $9K | |
| 86701 | <1% | 3,740 | $9K | |
| 86337 | <1% | 942 | $9K | |
| 86886 | <1% | 2,944 | $9K | |
| 86334 | <1% | 1,328 | $9K | |
| 87101 | <1% | 2,087 | $8K | |
| 80184 | <1% | 2,982 | $8K | |
| 82679 | <1% | 671 | $8K | |
| 83721 | <1% | 2,804 | $8K | |
| 81050 | <1% | 4,107 | $8K | |
| 86631 | <1% | 417 | $8K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 4,995 | $7K |
| 82310 | <1% | 5,614 | $7K | |
| 84244 | <1% | 831 | $7K | |
| 83921 | <1% | 1,232 | $7K | |
| 82525 | <1% | 1,309 | $7K | |
| 84166 | <1% | 1,523 | $7K | |
| 84155 | <1% | 9,335 | $7K | |
| 82085 | <1% | 1,595 | $7K | |
| 82653 | <1% | 700 | $6K | |
| 88112 | <1% | 306 | $6K | |
| 86618 | <1% | 680 | $6K | |
| 86359 | <1% | 381 | $6K | |
| 80235 | <1% | 951 | $6K | |
| 82157 | <1% | 407 | $6K | |
| 84132 | <1% | 3,789 | $6K | |
| 86632 | <1% | 416 | $6K | |
| 82626 | <1% | 384 | $6K | |
| 87076 | <1% | 1,352 | $5K | |
| 86747 | <1% | 416 | $5K | |
| 81241 | <1% | 213 | $5K | |
| 80051 | <1% | 3,737 | $5K | |
| 82104 | <1% | 710 | $5K | |
| 80353 | <1% | 1,095 | $5K | |
| 80362 | <1% | 12,981 | $5K | |
| 89055 | <1% | 2,248 | $5K | |
| 83521 | <1% | 670 | $5K | |
| 86301 | <1% | 946 | $4K | |
| 82270 | <1% | 3,902 | $4K | |
| 87425 | <1% | 611 | $4K | |
| 85306 | <1% | 478 | $4K | |
| 87662 | <1% | 280 | $4K | |
| 80201 | <1% | 958 | $4K | |
| 80363 | <1% | 741 | $4K | |
| 82657 | <1% | 290 | $4K | |
| 88262 | <1% | 123 | $4K | |
| 86355 | <1% | 222 | $4K | |
| 82164 | <1% | 922 | $4K | |
| 82180 | <1% | 915 | $4K | |
| 86256 | <1% | 774 | $3K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13,895 | $3K |
| 88230 | <1% | 126 | $3K | |
| 82955 | <1% | 635 | $3K | |
| 84075 | <1% | 3,411 | $3K | |
| 84520 | <1% | 4,458 | $3K | |
| 83527 | <1% | 485 | $3K | |
| 82340 | <1% | 887 | $3K | |
| 85303 | <1% | 439 | $3K | |
| 86357 | <1% | 178 | $3K | |
| 87341 | <1% | 566 | $3K | |
| 99001 | <1% | 2,040 | $3K | |
| 86768 | <1% | 385 | $3K | |
| 86794 | <1% | 339 | $3K | |
| 80203 | <1% | 448 | $3K | |
| 84597 | <1% | 627 | $3K | |
| 87427 | <1% | 428 | $3K | |
| 87210 | <1% | 954 | $3K | |
| 80321 | <1% | 389 | $3K | |
| 83630 | <1% | 256 | $3K | |
| 88185 | <1% | 29 | $2K | |
| 84080 | <1% | 464 | $2K | |
| 82530 | <1% | 258 | $2K | |
| 87328 | <1% | 286 | $2K | |
| 83935 | <1% | 874 | $2K | |
| 0097U | <1% | 672 | $2K | |
| 82272 | <1% | 1,970 | $2K | |
| 82040 | <1% | 2,770 | $2K | |
| 84482 | <1% | 405 | $2K | |
| 80162 | <1% | 1,124 | $2K | |
| 80202 | <1% | 369 | $2K | |
| 86300 | <1% | 231 | $2K | |
| 86622 | <1% | 338 | $2K | |
| 80325 | <1% | 6,983 | $2K | |
| 87593 | <1% | 60 | $2K | |
| 83930 | <1% | 722 | $2K | |
| 86162 | <1% | 281 | $2K | |
| 82985 | <1% | 292 | $2K | |
| 85300 | <1% | 248 | $2K | |
| 84300 | <1% | 955 | $2K | |
| 87538 | <1% | 100 | $1K | |
| 83704 | <1% | 347 | $1K | |
| 86609 | <1% | 259 | $1K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 202 | $1K |
| 80165 | <1% | 258 | $1K | |
| 86703 | <1% | 225 | $1K | |
| 81329 | <1% | 30 | $1K | |
| 83835 | <1% | 189 | $1K | |
| 87185 | <1% | 478 | $1K | |
| 82139 | <1% | 129 | $1K | |
| 87205 | <1% | 660 | $1K | |
| 87535 | <1% | 100 | $1K | |
| 83003 | <1% | 135 | $1K | |
| 88280 | <1% | 125 | $1K | |
| 86356 | <1% | 67 | $1K | |
| 84182 | <1% | 74 | $1K | |
| 81240 | <1% | 39 | $950.28 | |
| 82668 | <1% | 224 | $895.83 | |
| 87102 | <1% | 257 | $864.68 | |
| 80299 | <1% | 1,065 | $851.79 | |
| 87220 | <1% | 327 | $821.45 | |
| 86363 | <1% | 108 | $818.29 | |
| 82705 | <1% | 326 | $803.07 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 3,229 | $799.10 |
| 84145 | <1% | 268 | $781.64 | |
| 82379 | <1% | 86 | $774.97 | |
| 88291 | <1% | 148 | $747.39 | |
| 87107 | <1% | 126 | $701.75 | |
| 81507 | <1% | 31 | $642.75 | |
| 84238 | <1% | 42 | $621.90 | |
| 83992 | <1% | 164 | $566.37 | |
| 88302 | <1% | 24 | $544.00 | |
| 84591 | <1% | 149 | $536.64 | |
| 85049 | <1% | 465 | $505.58 | |
| 36416 | <1% | 4,688 | $492.67 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 503 | $472.22 |
| 85004 | <1% | 380 | $458.74 | |
| 82595 | <1% | 224 | $431.98 | |
| 86707 | <1% | 137 | $413.91 | |
| 88184 | <1% | 29 | $378.52 | |
| 84133 | <1% | 154 | $327.79 | |
| 86037 | <1% | 96 | $319.85 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 509 | $316.14 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 28 | $316.11 |
| 86231 | <1% | 56 | $311.28 | |
| 86905 | <1% | 108 | $286.56 | |
| 86148 | <1% | 40 | $284.34 | |
| 83605 | <1% | 47 | $276.96 | |
| 86880 | <1% | 96 | $267.68 | |
| 84252 | <1% | 40 | $264.77 | |
| 84378 | <1% | 59 | $234.88 | |
| 80198 | <1% | 168 | $232.67 | |
| 80360 | <1% | 193 | $208.19 | |
| 83718 | <1% | 61 | $197.88 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 417 | $192.36 |
| 86596 | <1% | 57 | $186.06 | |
| 81381 | <1% | 729 | $183.12 | |
| 82642 | <1% | 16 | $177.06 | |
| 81243 | <1% | 12 | $172.83 | |
| 83874 | <1% | 47 | $167.80 | |
| 80339 | <1% | 31 | $161.81 | |
| 82436 | <1% | 46 | $135.54 | |
| 87337 | <1% | 28 | $127.46 | |
| 84295 | <1% | 184 | $120.85 | |
| 85046 | <1% | 44 | $117.02 | |
| 83625 | <1% | 15 | $113.99 | |
| 83018 | <1% | 12 | $112.98 | |
| 82175 | <1% | 13 | $112.68 | |
| 80335 | <1% | 704 | $109.16 | |
| 87181 | <1% | 66 | $108.25 | |
| 83825 | <1% | 14 | $96.57 | |
| 82077 | <1% | 55 | $90.15 | |
| 88155 | <1% | 12 | $67.45 | |
| 80366 | <1% | 58 | $58.57 | |
| 82232 | <1% | 15 | $50.31 | |
| 83529 | <1% | 67 | $43.87 | |
| 87172 | <1% | 17 | $35.75 | |
| G0476 | Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test | <1% | 12 | $27.38 |
| 85670 | <1% | 14 | $24.24 | |
| 85651 | <1% | 12 | $17.11 | |
| 82374 | <1% | 26 | $13.46 | |
| 83519 | 0% | 119 | $0.00 | |
| T4534 | Youth sized disposable incontinence product, protective underwear/pull-on, each | 0% | 12 | $0.00 |
| 80340 | 0% | 47 | $0.00 | |
| 82435 | 0% | 38 | $0.00 | |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | 0% | 25 | $0.00 |
| 80334 | 0% | 33 | $0.00 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 0% | 127 | $0.00 |
| 80356 | 0% | 14 | $0.00 | |
| 80338 | 0% | 33 | $0.00 | |
| G0141 | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSILBERMAN, MARK (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Symphony Medical PC | Dobbs Ferry, NY | $3.72M |
| Dobbs Ferry Emergency Medicine, PC | Dobbs Ferry, NY | $3.08M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.